Coffey is part of a trial sponsored by the drug company Pfizer awaiting approval in the United Kingdom that will slip a patch of hESC - derived RPE
cells under the retina instead of injecting them in a liquid suspension.
Not exact matches
The volunteers, ranging in age from 20 to 88, received injections
under their
retina of a particular type of eye
cell, retinal pigment epithelium (RPE)
cells, which were derived from hESCs in the lab.
«When this chip is put into the eye
under the
retina, its solar
cells and the electrodes come into contact with the poorly functioning light - sensing
cells,» says Alan Chow.
The researchers injected 50,000 RPE
cells suspended in a solution
under the
retina in one eye of each patient.
In theory, Apte said, when most of the ganglion
cells in the
retina already have died, fewer
cells would be
under stress, and that could mean lower levels.
Another delivery showing promise is a suspension of
cells, which is injected into the eye
under the
retina.